Metaclipse Therapeutics Corporation products

Metaclipse Therapeutics Corporation is developing novel personalized vaccine immunotherapies for cancer. Membrex^TM, a proprietary platform approach tailored to each patient and their specific tumor, consists of ‘membrane vesicles’ prepared from a patient’s tumor tissue that Metaclipse modifies with a ‘protein transfer’ method using proven immunostimulatory proteins. After intradermal administration, these modified vesicles deliver both immunostimulatory proteins, which act as adjuvants, and an array of patient-specific tumor-membrane antigens simultaneously to the immune system. This creates robust tumor-specific immunity that Metaclipse anticipates will destroy and/or suppress the growth of metastatic cancer cells. Our preclinical studies demonstrated that our vaccine immunotherapy acts via T cells and thus potentially inducing immune memory against cancers.

Influenza (Target age 65+) and Influenza+ SARS-C0V-2 Combination